BioCorRx Inc. (BICX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioCorRx Inc. (BICX) with AI Score 52/100 (Hold). BioCorRx Inc. develops and provides treatment programs for substance abuse and related disorders in the United States. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026BioCorRx Inc. (BICX) Healthcare & Pipeline Overview
BioCorRx Inc. focuses on developing and distributing treatment programs for substance abuse and weight management, featuring its BioCorRx recovery program and UnCraveRx. Operating within the medical care facilities sector, the company leverages medication-assisted treatments and virtual support to address addiction and weight-related disorders in the United States.
Investment Thesis
BioCorRx Inc. presents a speculative investment opportunity within the substance abuse and weight management sectors. The company's proprietary naltrexone implant technology and the UnCraveRx program offer potential revenue streams, though profitability remains a challenge, as reflected in the negative P/E ratio of -1.41 and a substantial negative profit margin of -510.3%. The development of BICX101 and BICX104 could serve as future catalysts, pending regulatory approvals and successful clinical trials. The company's small market capitalization of $0.01 billion and limited number of employees (3) suggest a high-risk, high-reward scenario, contingent on successful product commercialization and market penetration. Investors should carefully consider the company's financial position and the competitive landscape before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion, indicating a micro-cap company with high growth potential but also significant risk.
- P/E ratio of -1.41, reflecting current unprofitability but potential for future earnings growth.
- Gross margin of 53.9%, suggesting a solid foundation for profitability if operational costs are managed effectively.
- Negative profit margin of -510.3%, highlighting significant challenges in achieving profitability.
- Beta of 0.30, indicating lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary naltrexone implant technology.
- Integrated counseling and medication-assisted treatment approach.
- Virtual support platform for weight management.
- Development pipeline of new naltrexone products (BICX101, BICX104).
Weaknesses
- Small market capitalization and limited resources.
- Negative profitability and high operating expenses.
- Reliance on a small number of employees.
- OTC market listing, which may limit investor access.
Catalysts
- Upcoming: Potential FDA approval of BICX101 (injectable naltrexone).
- Upcoming: Potential FDA approval of BICX104 (implantable naltrexone).
- Ongoing: Expansion of the BioCorRx recovery program to new healthcare providers.
- Ongoing: Growth in sales of the UnCraveRx weight loss management program.
- Ongoing: Strategic partnerships and acquisitions.
Risks
- Potential: Regulatory delays or rejection of BICX101 and BICX104.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: Negative profitability and high operating expenses.
- Ongoing: Reliance on a small number of employees.
- Ongoing: Limited financial disclosure due to OTC listing.
Growth Opportunities
- Expansion of the BioCorRx Recovery Program: The market for medication-assisted treatment (MAT) is growing, driven by the opioid crisis and increasing acceptance of MAT as an effective treatment modality. BioCorRx can expand its reach by partnering with more healthcare providers and clinics across the United States. The addressable market for MAT is estimated to be billions of dollars, offering significant growth potential for BioCorRx.
- Development and Commercialization of BICX101 and BICX104: The successful development and approval of BICX101 (injectable naltrexone) and BICX104 (implantable naltrexone) represent significant growth opportunities. These products could provide more convenient and effective treatment options for opioid addiction and alcoholism. The market for long-acting injectable and implantable naltrexone products is substantial, with potential for significant revenue generation upon successful commercialization.
- Growth of the UnCraveRx Weight Loss Management Program: The weight loss market is a multi-billion dollar industry, driven by increasing obesity rates and demand for effective weight management solutions. BioCorRx can expand its UnCraveRx program by enhancing its virtual support platform, adding new features, and targeting specific customer segments. The program's medically assisted approach and virtual support offer a differentiated value proposition.
- Strategic Partnerships and Acquisitions: BioCorRx can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and market share. Collaborating with other healthcare providers, technology companies, or pharmaceutical companies could accelerate growth and enhance the company's competitive position. Potential acquisition targets could include companies with complementary technologies or treatment programs.
- International Expansion: While currently focused on the United States, BioCorRx can explore opportunities for international expansion. The need for substance abuse and weight management solutions exists globally, and BioCorRx's programs could be adapted for use in other countries. International expansion would require careful planning and execution, but it could significantly expand the company's addressable market and revenue potential.
Opportunities
- Expansion of the BioCorRx recovery program to more healthcare providers.
- Commercialization of BICX101 and BICX104.
- Growth of the UnCraveRx weight loss management program.
- Strategic partnerships and acquisitions.
Threats
- Competition from established pharmaceutical companies and treatment centers.
- Regulatory hurdles and potential delays in product approvals.
- Changes in healthcare policies and reimbursement rates.
- Potential for product liability claims.
Competitive Advantages
- Proprietary naltrexone implant technology.
- Integrated counseling program with medication-assisted treatment.
- Virtual support platform for weight management.
- Development of new injectable and implantable naltrexone products.
About BICX
BioCorRx Inc., formerly known as Fresh Start Private Management, Inc. until its name change in January 2014, is dedicated to developing and providing treatment programs for substance abuse and related disorders in the United States. The company's core offering includes the BioCorRx recovery program, a non-addictive, medication-assisted treatment that combines a counseling program with its proprietary naltrexone implant. This program is distributed and licensed to healthcare providers, independent licensed clinics, and licensed healthcare professionals. In addition to substance abuse treatment, BioCorRx also offers the UnCraveRx weight loss management program. This medically assisted program aims to reduce food cravings through medication, coupled with on-demand virtual lifestyle support, fitness resources, and nutritional guidance. This dual approach addresses both addiction and weight management, reflecting a comprehensive approach to health and wellness. BioCorRx is also actively developing new products, including BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant specifically designed for the treatment of opioid addiction and alcoholism. These pipeline products indicate the company's commitment to expanding its treatment options and addressing critical needs in the addiction treatment landscape. Headquartered in Anaheim, California, BioCorRx operates primarily within the United States, focusing on providing innovative solutions for substance abuse and weight management.
What They Do
- Develops treatment programs for substance abuse and related disorders.
- Provides medication-assisted treatment programs.
- Distributes and licenses the BioCorRx recovery program, a non-addictive treatment.
- Offers a counseling program coupled with a proprietary naltrexone implant.
- Distributes the UnCraveRx weight loss management program.
- Provides medically assisted weight management to reduce food cravings.
- Offers on-demand virtual lifestyle support, fitness, and nutrition.
- Develops BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant.
Business Model
- Licensing and distribution of the BioCorRx recovery program to healthcare providers and clinics.
- Direct sales of the UnCraveRx weight loss management program to individuals.
- Potential future revenue from sales of BICX101 and BICX104 upon regulatory approval.
- Partnerships with healthcare professionals for program implementation.
Industry Context
BioCorRx Inc. operates within the medical care facilities industry, addressing the growing needs for substance abuse and weight management solutions. The market for addiction treatment is expanding, driven by increasing awareness and the opioid crisis. The weight management market is also substantial, fueled by rising obesity rates and demand for effective solutions. BioCorRx competes with companies like BVAXF, FAMDF, GBCS, HLYK, and IONKF, which offer various treatment options and programs. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and effectively market its programs to healthcare providers and individuals.
Key Customers
- Healthcare providers and independent licensed clinics.
- Licensed healthcare professionals.
- Individuals seeking treatment for substance abuse.
- Individuals seeking medically assisted weight management solutions.
Financials
Chart & Info
BioCorRx Inc. (BICX) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 2, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BICX.
Price Targets
Wall Street price target analysis for BICX.
MoonshotScore
What does this score mean?
The MoonshotScore rates BICX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lourdes Felix
Unknown
Information about Lourdes Felix's background is not available in the provided context. Without additional data, it is impossible to provide details about her career history, education, or previous roles. Her professional experience and qualifications remain unknown based on the current information.
Track Record: Due to the limited information available, it is not possible to assess Lourdes Felix's track record or key achievements as CEO. Her strategic decisions and company milestones under her leadership cannot be evaluated without further data on her tenure and performance.
BICX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioCorRx Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to NYSE or NASDAQ-listed companies. These companies often do not adhere to standardized accounting practices, increasing the potential for fraud or misrepresentation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or misrepresentation.
- Low liquidity and potential for price volatility.
- Limited regulatory oversight and investor protection.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Existence of a physical headquarters in Anaheim, California.
- Development of proprietary naltrexone implant technology.
- Distribution of the BioCorRx recovery program.
- Offering of the UnCraveRx weight loss management program.
- Development pipeline of new naltrexone products (BICX101, BICX104).
BICX Healthcare Stock FAQ
What does BioCorRx Inc. do?
BioCorRx Inc. develops and provides treatment programs for substance abuse and weight management. Its primary product is the BioCorRx recovery program, which combines counseling with a proprietary naltrexone implant to treat addiction. The company also offers the UnCraveRx weight loss management program, a medically assisted program with virtual support. Additionally, BioCorRx is developing BICX101 and BICX104, injectable and implantable naltrexone products, respectively, aimed at treating opioid addiction and alcoholism. BioCorRx distributes its programs to healthcare providers and licensed professionals.
What do analysts say about BICX stock?
There is currently no available analyst coverage or consensus on BioCorRx Inc. (BICX) due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and ratings are unavailable. Potential investors should conduct their own due diligence and consider the company's financial position, growth prospects, and risk factors before making any investment decisions. The lack of analyst coverage highlights the speculative nature of this investment.
What are the main risks for BICX?
BioCorRx Inc. faces several key risks, including its small market capitalization, negative profitability, and reliance on a limited number of employees. As an OTC-listed company, it has limited financial disclosure and liquidity, increasing the risk of price volatility and potential fraud. The company's success depends on the successful development and commercialization of BICX101 and BICX104, which are subject to regulatory approval and competition from established pharmaceutical companies. Changes in healthcare policies and reimbursement rates could also negatively impact the company's financial performance.
What are the key factors to evaluate for BICX?
BioCorRx Inc. (BICX) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary naltrexone implant technology.. Primary risk to monitor: Potential: Regulatory delays or rejection of BICX101 and BICX104.. This is not financial advice.
How frequently does BICX data refresh on this page?
BICX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BICX's recent stock price performance?
Recent price movement in BioCorRx Inc. (BICX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary naltrexone implant technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BICX overvalued or undervalued right now?
Determining whether BioCorRx Inc. (BICX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BICX?
Before investing in BioCorRx Inc. (BICX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- Lack of analyst coverage limits the availability of expert opinions.